The CTNEoBC pooled analysis has confirmed that patients with HER2-overexpressing breast cancer who received neoadjuvant HER2-targeted therapy were more likely to achieve higher pCR rates which are associated with better long-term survival (6). This evidence concerns the gene ERBB2 and breast cancer.